While the PBM Express Scripts declared plans to bring cancer drug plans down, the drug manufacturers and investors aren't too worried about the high cost of some of the specialty drugs, according to this article in Bloomberg.
President Barack Obama, prominent cancer doctors and health insurers are all warning about the need to control the surging prices of new drugs.
Drugmakers and their investors aren’t acting worried at all, especially when it comes to cancer medicine. In the wake of AbbVie Inc’s $21 billion pact to buy the maker of a $100,000-a-year leukemia drug, the pharmaceutical industry and Wall Street are signaling they don’t expect the brakes on pricing any time soon in the oncology field. Companies that are developing cancer drugs rose in reaction to both the deal and regulatory approval of a $12,500-a-month treatment from Bristol-Myers Squibb Co for treating a lung malignancy.
“Oncology is a different ballgame,” AbbVie Chief Executive Officer Rick Gonzalez said in an interview. “You’re talking about life and death for these patients, it is not something you want to randomly start to manage in a way that would create risk for those patients.”
Link to the complete article in Bloomberg: http://bloom.bg/1AXvtBI
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
July 30th 2024On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Listen